Editing the Genome to Cure Genetic Disease

Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer. Our aim: to transform the lives of patients and families affected by genetic disease.

Social Media

Amy Duross @vinetiworks leads our Technology Trends panel, discussing leading platforms across cell & gene therapy sector, feat @pfizer @casebiatx @BlueRockTx @Adaptimmune #CGDay18

CEO, Jim Burns is in New York City this morning at @Alliancerm Cell & Gene Investor day participating in a panel: "Tech Trends: Leading Platforms Across the Cell and Gene Sector". 10:25am - Don't miss it! #CGDAY18

Casebia knows what day it is… #OpeningDay Cheering on the @RedSox from across the river! Go Sox!

Casebia’s own Robin Walker, VP Head of Legal and @ArevaMartin “Make it Rain” at the ACC-Northeast breakfast this morning in Boston. Thanks to @MintzLevin and @accinhouse for hosting the “Rise to Influence – Developing Your Brand to Lead and Succeed!"

Tackling the Intractable: Future of Cardiovascular Diseases Panel @MassBio Annual Meeting

See us on Twitter